Navigation Links
BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
Date:5/1/2008

s for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, futur
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMS Medical to present at EQUITIES Conference
2. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
3. BioMS Medical to present at BioCentury Conference
4. BioMS Medical Announces 2007 Year End Results
5. BioMS Medical to present at BIO CEO & Investor Conference
6. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces third quarter 2007 results
10. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
11. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for the ... system received a score of 0 (range -10 to +10) for its impact on ... Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes to ...
(Date:7/29/2015)... CITY , July 29, 2015 /PRNewswire/ - Aeterna ... today announced it has selected an optimized Erk ... milestone in the development of a new class ... MAPK pathway represents a prime target for therapeutic ... antitumor activities and survival benefits for B-Raf and ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi ... Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in ... core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site ...
(Date:7/29/2015)... ... , ... Costello served as Lead Levee Design Engineering Manager for a feasibility ... area from future storm surge flooding, such as occurred in Hurricane Ike in 2008. ... for providing protection, Costello also balanced socio-economic and environmental needs and concerns. ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2
... CITY, Calif., Sept. 13 Abaxis, Inc.,(Nasdaq: ... analysis systems, announced today that Clint Severson, CEO ... LLC Sixth Annual San,Francisco Institutional Investor Forum Conference ... Time at The Ritz-Carlton Hotel in San Francisco. ...
... JOSE, Calif., Sept. 13 Micrus,Endovascular Corporation (Nasdaq: ... of Stockholders will be broadcast live over the,Internet on ... (9:00,a.m. Pacific time). Those listening to the meeting via ... ask questions during the,meeting. What: Micrus Endovascular ...
... Exchange Agreement, COPENHAGEN, September 13 Genmab ... asset exchange agreement with,Medarex, Inc. Under the terms ... HuMax-Inflam(TM)/MDX-018, which targets IL-8, and Medarex will,receive full ... and,Medarex will release to each other all previously ...
Cached Biology Technology:Micrus Endovascular to Webcast Fiscal 2007 Annual Meeting of Stockholders 2Genmab Announces Asset Exchange Agreement 2
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... University of Manchester scientists have discovered for the first time ... (HPV) triggers cancer in what could lead to new treatments ... to increase the risk of developing cancers of the cervix ... accounting for approximately 70% of all cervical cancer cases. ...
... , This release is available in Spanish ... Biology and Regenerative Medicine (CABIMER) and the University of ... apoptosis is not only essential in breast tumor cells resistance ... potential against cancer), but this protein is also key to ...
... NY - One big challenge in converting plants to biofuels ... up make it hard to break them down. Now scientists ... are unraveling details of how plant cells, structural supports - ... finding ways to change their composition for more efficient biofuel ...
Cached Biology News:Scientists identify how virus triggers cervical and mouth cancer 2A protein called cFLIP makes tumor cells in breast cancer resistant to treatments 2Scientists unravel more details of plant cell-wall construction 2
... System combines 2 products into 1:, , ... molecular isolation kit , ,The FastPrep ... and Qbiogene/BIO101 System Matrix and Isolation Kits. ... micro tubes eliminating the use of metal ...
... ,Each upright model provides fast pull-down, ... uniformity for refrigerated blood. The BBR25 and ... for complete blood storage monitoring. Models BBR6, ... the HemaPro 101 alarm/monitor. All of these ...
... form of Tobacco Etch Virus (TEV) protease ... significantly more stable than native TEV protease, ... recognizes a seven amino acid (Glu-Asn-Leu-Tyr-Phe-Gln-Gly, cleaving ... for removing affinity tags from fusion proteins ...
S-100A10 (H-80)...
Biology Products: